A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Castration-Resistant Prostate Cancer Clinical Trial

Official title:

An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02578797
• Other study ID #: CR108049
• Secondary ID: 2015-004044-1956
• Status: Completed
• Phase: Phase 1
• Start date: December 18, 2015
• Est. completion date: October 13, 2022

Study information

• Verified date: November 2023
• Source: Aragon Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether daily treatment with apalutamide affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC)

Description:

This is an open-label (a study in which the drug, procedure is known to participant and investigator), multicenter, Phase 1b study to investigate the effect of apalutamide on ventricular repolarization at a dose level of 240 milligram (mg daily). Approximately 42 participants with high-risk non-metastatic prostate cancer (NM-CRPC), defined as having a prostate specific antigen (PSA) doubling time less than or equal to (<=) 10 months, or participants with metastatic CRPC will be enrolled. The study consists of a 28-day Screening Phase, a Treatment Phase and a Follow-up Phase. In the Treatment Phase the study drug will be administrated in cycles of 28 days and the participants will be monitored for safety (including cardiac safety) and pharmacokinetics of the study drug. Adverse Events will be monitored throughout the study and in the Follow-up Phase until 30 days after the last dose of study drug. All participants will continue on study until disease progression, withdrawal of consent, lost to follow-up, the occurrence of unacceptable toxicity, the participant is no longer receiving clinical benefit in the opinion of the investigator, or termination of the study by the sponsor. Upon discontinuation of study drug, the participants will return for an End-of-Treatment (EoT) visit no later than 30 days after their last dose. The end of the study corresponds to the clinical cutoff and end of data collection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: October 13, 2022
• Est. primary completion date: September 20, 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

• Adenocarcinoma of the prostate; either non-metastatic castrate resistant prostate cancer (NM-CRPC) with high risk disease (defined as PSA Doubling time equal or less than (<=) 10 months) or metastatic CRPC

• Be surgically or medically castrated with testosterone levels of less than (<) 50 nanogram per deciliter

• If treated with a gonadotropin releasing hormone analog (ie, patient who has not undergone bilateral orchiectomy), then this therapy must have been initiated at least 4 weeks prior to Cycle 1 Day 1 and must be continued throughout the study

• Electrocardiogram (ECG) showing a QT interval corrected for heart rate, using Fridericia formula (QTcF) <= 470 milliseconds (based on the average of a triplicate ECG set collected during the screening visit)

• Left ventricular ejection fraction (LVEF) of more than 45% as determined by multiple uptake gated acquisition (MUGA) or echocardiography at the screening visit

Exclusion Criteria:

• Abnormal cardiac function at screening

• Known brain metastases

• Has received an investigational drug within 4 weeks, or within a period < 10 times the drug's half-life, whichever is longer, of Cycle 1 Day 1

• Has received chemotherapy or immunotherapy for the treatment of prostate cancer within 4 weeks of Cycle 1 Day 1

• Prior treatment with enzalutamide and apalutamide

• Use of therapies that must be discontinued or substituted within at least 4 weeks prior to Cycle 1 Day 1 including medications to lower seizure threshold, inducing/inhibiting metabolizing enzymes or prolonging the QT interval

• History or condition that may predispose to seizures, or evidence of severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events within 12 months prior to Cycle 1 Day 1, New York Heart Association (NYHA) Class II to IV heart disease

Related Conditions & MeSH terms

• Castration-Resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Apalutamide
Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Aragon Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Moldova, Republic of,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	QTc Fridericia (QTcF) parameter	Mean change from baseline in QTcF as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake.	Day-1 and Day 1 (Cycle 1) and Day 1 (Cycle 3)
Secondary	Electrocardiographic parameters (HR, RR, PR, and QRS)	A change from time-matched baseline measurements in HR, PR, RR and QRS interval will be determined on Day -1, Day 1 and Day 3	Day-1 and Day 1 (Cycle 1) and Day 1 (Cycle 3)
Secondary	Electrocardiographic parameters (QT)	QT interval on a surface ECG will be corrected for heart rate using Bazett formula (QTcB) and study-specific Power (QTcP) if appropriate at each treatment period.	Day-1 and Day 1 (Cycle 1) and Day 1 (Cycle 3)
Secondary	Electrocardiographic parameters T- and U-wave morphology	Number and percentage of participants with changes from baseline	Day-1 and Day 1 (Cycle 1) and Day 1 (Cycle 3)
Secondary	Plasma concentrations apalutamide (and its active metabolite JNJ-56142060)	Blood samples will be taken following dose administration.	Day-1, Day 1 and Day 2 (Cycle 1) and Day 1 (Cycle 3)
Secondary	Number of participants with Adverse Events	Participants will be monitored for safety during the Screening and Treatment Phases, and up to 30 days after the last dose of study drug. From Cycle 4 onward collection of Adverse Events (AEs) will be limited to Grade 3 or higher and all Serious AEs from the remainder of the study.	Day-1, Day 1 and Day 15 (Cycle 1); Day 1 and Day 15 (Cycle 2) and Day 1 (Cycle 3).
Secondary	Pharmacokinetic parameter area under the plasma drug concentration-time curve (AUC) from time 0 to 24 hours	The AUC(0-24h) is the area under the plasma concentration-time curve from time 0 to time 24 hours after dosing.	Day 1 and Day 2 (Cycle 1) and Day 1 (Cycle 3)
Secondary	Pharmacokinetic parameter maximum concentration observed (Cmax)	The Cmax is the maximum observed plasma concentration.	Day 1 and Day 2 (Cycle 1) and Day 1 (Cycle 3)
Secondary	Pharmacokinetic parameter time to reach Cmax (tmax)	The tmax is the time to reach the maximum observed plasma concentration.	Day 1 and Day 2 (Cycle 1) and Day 1 (Cycle 3)
Secondary	Pharmacokinetic parameter minimum observed plasma concentration (Cmin)	The Cmin is the minimum observed plasma concentration.	Cmin will only be collected on Day 1, Cycle 3